Yuan Yuan, Yatong Zhang, Li Zheng, Xiaotong Gu, Shaohua Yu, Xuelin Sun
{"title":"对白癜风患者使用芦可利替尼乳膏的短期（24周）疗效和安全性：系统综述和荟萃分析。","authors":"Yuan Yuan, Yatong Zhang, Li Zheng, Xiaotong Gu, Shaohua Yu, Xuelin Sun","doi":"10.1186/s13643-024-02653-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Vitiligo is a chronic skin disorder causing depigmentation. There is a lack of evidence-based medical evidence regarding ruxolitinib efficacy and safety for vitiligo.</p><p><strong>Objective: </strong>To assess the efficacy and safety of ruxolitinib cream in the treatment of vitiligo.</p><p><strong>Methods: </strong>The databases of PubMed, Embase, and Cochrane Library were searched. The literature screening was independently conducted by two reviewers.</p><p><strong>Data extraction and synthesis: </strong>For continuous variables, weighted mean difference (WMD) along with a 95% confidence interval (CI) was performed. For dichotomous outcomes, we calculated the odds ratios (ORs) or risk ratios (RRs), and their corresponding 95% CIs. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE).</p><p><strong>Main outcomes and measures: </strong>Symptoms, quality of life, and safety were evaluated using various measures, including the Facial Vitiligo Area Scoring Index (F-VASI), Total Vitiligo Area Scoring Index (T-VASI), Facial Body Surface Area (F-BAS), Total Body Surface Area (T-BAS) and Treatment-emergent Adverse Events (TEAEs).</p><p><strong>Results: </strong>Three trials, involving a total of 830 participants from nine countries were included (female 388, 46.7%, male 442, 53.3%). The meta-analysis demonstrated a significant increase in the likelihood of participants achieving F-VASI75 (OR, 4.34 [95% CI 2.67-7.06]; high), F-VASI50 (OR 4.71 [95% CI 3.24-6.84]; high), T-VASI75 (OR 2.78 [95% CI 1.10-7.00]; moderate), and T-VASI50 (OR 4.47 [95% CI 2.52-7.92]; high) when compared ruxolitinib to vehicle. Ruxolitinib was associated with more lowered percentage change of F-VASI scores (MD - 32.79 [95% CI - 36.37 to - 29.21]; moderate), and T-VASI scores (MD - 20.22 [95% CI - 23.11 to - 17.33]; moderate) from baseline compared to vehicle. There may not be a significant difference in the occurrence of TEAEs between ruxolitinib and vehicle (RR 1.46 [95% CI 0.85-2.49]; high).</p><p><strong>Conclusions: </strong>The findings suggest that ruxolitinib cream holds promise as a treatment option for vitiligo. Further long-term studies are needed to assess its sustained efficacy and safety profile.</p><p><strong>Systematic review registration: </strong>PROSPERO CRD42023431112.</p>","PeriodicalId":22162,"journal":{"name":"Systematic Reviews","volume":"13 1","pages":"250"},"PeriodicalIF":6.3000,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11445846/pdf/","citationCount":"0","resultStr":"{\"title\":\"Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis.\",\"authors\":\"Yuan Yuan, Yatong Zhang, Li Zheng, Xiaotong Gu, Shaohua Yu, Xuelin Sun\",\"doi\":\"10.1186/s13643-024-02653-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Importance: </strong>Vitiligo is a chronic skin disorder causing depigmentation. There is a lack of evidence-based medical evidence regarding ruxolitinib efficacy and safety for vitiligo.</p><p><strong>Objective: </strong>To assess the efficacy and safety of ruxolitinib cream in the treatment of vitiligo.</p><p><strong>Methods: </strong>The databases of PubMed, Embase, and Cochrane Library were searched. The literature screening was independently conducted by two reviewers.</p><p><strong>Data extraction and synthesis: </strong>For continuous variables, weighted mean difference (WMD) along with a 95% confidence interval (CI) was performed. For dichotomous outcomes, we calculated the odds ratios (ORs) or risk ratios (RRs), and their corresponding 95% CIs. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE).</p><p><strong>Main outcomes and measures: </strong>Symptoms, quality of life, and safety were evaluated using various measures, including the Facial Vitiligo Area Scoring Index (F-VASI), Total Vitiligo Area Scoring Index (T-VASI), Facial Body Surface Area (F-BAS), Total Body Surface Area (T-BAS) and Treatment-emergent Adverse Events (TEAEs).</p><p><strong>Results: </strong>Three trials, involving a total of 830 participants from nine countries were included (female 388, 46.7%, male 442, 53.3%). The meta-analysis demonstrated a significant increase in the likelihood of participants achieving F-VASI75 (OR, 4.34 [95% CI 2.67-7.06]; high), F-VASI50 (OR 4.71 [95% CI 3.24-6.84]; high), T-VASI75 (OR 2.78 [95% CI 1.10-7.00]; moderate), and T-VASI50 (OR 4.47 [95% CI 2.52-7.92]; high) when compared ruxolitinib to vehicle. Ruxolitinib was associated with more lowered percentage change of F-VASI scores (MD - 32.79 [95% CI - 36.37 to - 29.21]; moderate), and T-VASI scores (MD - 20.22 [95% CI - 23.11 to - 17.33]; moderate) from baseline compared to vehicle. There may not be a significant difference in the occurrence of TEAEs between ruxolitinib and vehicle (RR 1.46 [95% CI 0.85-2.49]; high).</p><p><strong>Conclusions: </strong>The findings suggest that ruxolitinib cream holds promise as a treatment option for vitiligo. Further long-term studies are needed to assess its sustained efficacy and safety profile.</p><p><strong>Systematic review registration: </strong>PROSPERO CRD42023431112.</p>\",\"PeriodicalId\":22162,\"journal\":{\"name\":\"Systematic Reviews\",\"volume\":\"13 1\",\"pages\":\"250\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2024-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11445846/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Systematic Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13643-024-02653-7\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Systematic Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13643-024-02653-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
重要性：白癜风是一种导致色素脱失的慢性皮肤疾病。目前尚缺乏有关芦可利替尼治疗白癜风疗效和安全性的循证医学证据：评估芦可利替尼乳膏治疗白癜风的有效性和安全性：方法：检索 PubMed、Embase 和 Cochrane Library 等数据库。文献筛选由两名审稿人独立完成：对于连续变量，采用加权平均差（WMD）和95%置信区间（CI）。对于二分结果，我们计算了几率比（OR）或风险比（RR）及其相应的 95% CI。证据的确定性采用建议、评估、发展和评价分级法（GRADE）进行评估：主要结果和测量方法：采用面部白癜风面积评分指数（F-VASI）、总白癜风面积评分指数（T-VASI）、面部体表面积（F-BAS）、总体表面积（T-BAS）和治疗突发不良事件（TEAEs）等多种测量方法对症状、生活质量和安全性进行评估：共纳入了三项试验，涉及来自九个国家的 830 名参与者（女性 388 人，占 46.7%；男性 442 人，占 53.3%）。荟萃分析表明，将Ruxolitinib与药物相比，参与者达到F-VASI75（OR，4.34 [95% CI 2.67-7.06]；高）、F-VASI50（OR 4.71 [95% CI 3.24-6.84]；高）、T-VASI75（OR 2.78 [95% CI 1.10-7.00]；中）和T-VASI50（OR 4.47 [95% CI 2.52-7.92]；高）的可能性显著增加。与治疗药物相比，Ruxolitinib可降低F-VASI评分（MD - 32.79 [95% CI - 36.37 to - 29.21]；中度）和T-VASI评分（MD - 20.22 [95% CI - 23.11 to - 17.33]；中度）自基线起的百分比变化。在TEAEs的发生率方面，Ruxolitinib和药物之间可能没有明显差异（RR 1.46 [95% CI 0.85-2.49]；高）：研究结果表明，Ruxolitinib乳膏有望成为治疗白癜风的一种选择。需要进一步开展长期研究，以评估其持续疗效和安全性：系统综述注册：PREMCORD42023431112。
Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis.
Importance: Vitiligo is a chronic skin disorder causing depigmentation. There is a lack of evidence-based medical evidence regarding ruxolitinib efficacy and safety for vitiligo.
Objective: To assess the efficacy and safety of ruxolitinib cream in the treatment of vitiligo.
Methods: The databases of PubMed, Embase, and Cochrane Library were searched. The literature screening was independently conducted by two reviewers.
Data extraction and synthesis: For continuous variables, weighted mean difference (WMD) along with a 95% confidence interval (CI) was performed. For dichotomous outcomes, we calculated the odds ratios (ORs) or risk ratios (RRs), and their corresponding 95% CIs. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE).
Main outcomes and measures: Symptoms, quality of life, and safety were evaluated using various measures, including the Facial Vitiligo Area Scoring Index (F-VASI), Total Vitiligo Area Scoring Index (T-VASI), Facial Body Surface Area (F-BAS), Total Body Surface Area (T-BAS) and Treatment-emergent Adverse Events (TEAEs).
Results: Three trials, involving a total of 830 participants from nine countries were included (female 388, 46.7%, male 442, 53.3%). The meta-analysis demonstrated a significant increase in the likelihood of participants achieving F-VASI75 (OR, 4.34 [95% CI 2.67-7.06]; high), F-VASI50 (OR 4.71 [95% CI 3.24-6.84]; high), T-VASI75 (OR 2.78 [95% CI 1.10-7.00]; moderate), and T-VASI50 (OR 4.47 [95% CI 2.52-7.92]; high) when compared ruxolitinib to vehicle. Ruxolitinib was associated with more lowered percentage change of F-VASI scores (MD - 32.79 [95% CI - 36.37 to - 29.21]; moderate), and T-VASI scores (MD - 20.22 [95% CI - 23.11 to - 17.33]; moderate) from baseline compared to vehicle. There may not be a significant difference in the occurrence of TEAEs between ruxolitinib and vehicle (RR 1.46 [95% CI 0.85-2.49]; high).
Conclusions: The findings suggest that ruxolitinib cream holds promise as a treatment option for vitiligo. Further long-term studies are needed to assess its sustained efficacy and safety profile.
期刊介绍：
Systematic Reviews encompasses all aspects of the design, conduct and reporting of systematic reviews. The journal publishes high quality systematic review products including systematic review protocols, systematic reviews related to a very broad definition of health, rapid reviews, updates of already completed systematic reviews, and methods research related to the science of systematic reviews, such as decision modelling. At this time Systematic Reviews does not accept reviews of in vitro studies. The journal also aims to ensure that the results of all well-conducted systematic reviews are published, regardless of their outcome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
